- Home
- FISV vs ONC Comparison
FISV vs ONC Comparison
Compare FISV & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FISV | ONC |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7B | 34.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FISV | ONC |
|---|---|---|
| Price | $59.87 | $352.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 30 | 12 |
| Target Price | $155.76 | ★ $370.25 |
| AVG Volume (30 Days) | ★ 9.5M | 301.0K |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.82 | N/A |
| EPS | ★ 6.48 | 0.58 |
| Revenue | ★ $21,160,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | N/A | $895.40 |
| Revenue Next Year | $2.23 | $22.04 |
| P/E Ratio | ★ $9.02 | $560.15 |
| Revenue Growth | 5.16 | ★ 50.43 |
| 52 Week Low | $57.79 | $196.45 |
| 52 Week High | $238.59 | $385.22 |
Technical Indicators
Market Signals| Indicator | FISV | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 31.65 | 55.15 |
| Support Level | $57.79 | $328.91 |
| Resistance Level | $60.88 | $355.43 |
| Average True Range (ATR) | 1.84 | 9.27 |
| MACD | -0.90 | 0.07 |
| Stochastic Oscillator | 10.33 | 65.61 |
Price Performance
Historical ComparisonAbout FISV Fiserv Inc.
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Following its 2019 merger with First Data, Fiserv also provides payment processing services to merchants. About 10% of the company's revenue is generated internationally.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.